Lidocaine transdermal patch - Immune Pharmaceuticals Inc

Drug Profile

Lidocaine transdermal patch - Immune Pharmaceuticals Inc

Alternative Names: ADL 87223; LidoPAIN BP; LidoPAIN HM; LidoPAIN SP; LidoPAIN TV

Latest Information Update: 23 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiCept Corporation
  • Developer EpiCept Corporation; Immune Pharmaceuticals Inc
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Back pain
  • Discontinued Headache; Postoperative pain; Tinnitus

Most Recent Events

  • 19 Jan 2018 No recent reports on development identified - Phase-II for Back pain in USA (Transdermal)
  • 31 Dec 2017 Immune Pharmaceuticals has patent protection for lidocaine transdermal patch in USA and Mexico
  • 31 Dec 2017 Immune Pharmaceuticals has patent pending for lidocaine transdermal patch in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top